Genomic and Precision Medicine Oncology Third Edition
Lymphomas: molecular subsets and advances in therapeutics
Publication
, Chapter
Dave, S
January 1, 2022
Lymphoma is the sixth most common cause of cancer death in any individual person in the United States and there are over 50 recognized individual lymphoma pathologic entities. Even within relatively common entities such as diffuse large B-cell lymphoma, there are subgroups now defined by gene expression signatures and other genomic markers. Advances in our understanding of the genomic underpinnings of these diseases have led the design of novel therapeutic strategies that have begun to change the outcome for patients that cannot be cured with standard therapies. This chapter reviews our current understanding of the genomic alterations in the most common lymphoma subtypes and discusses recent approaches in precision medicine for lymphomas.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Dave, S. (2022). Lymphomas: molecular subsets and advances in therapeutics. In Genomic and Precision Medicine Oncology Third Edition (pp. 85–102). https://doi.org/10.1016/B978-0-12-800684-9.00016-2
Dave, S. “Lymphomas: molecular subsets and advances in therapeutics.” In Genomic and Precision Medicine Oncology Third Edition, 85–102, 2022. https://doi.org/10.1016/B978-0-12-800684-9.00016-2.
Dave S. Lymphomas: molecular subsets and advances in therapeutics. In: Genomic and Precision Medicine Oncology Third Edition. 2022. p. 85–102.
Dave, S. “Lymphomas: molecular subsets and advances in therapeutics.” Genomic and Precision Medicine Oncology Third Edition, 2022, pp. 85–102. Scopus, doi:10.1016/B978-0-12-800684-9.00016-2.
Dave S. Lymphomas: molecular subsets and advances in therapeutics. Genomic and Precision Medicine Oncology Third Edition. 2022. p. 85–102.